Acta Med. 2023, 66: 154-157
https://doi.org/10.14712/18059694.2024.10
Self-reported Side Effects of SARS-CoV-2 Vaccination
References
1. J. Neurological Adverse Reactions to SARS-CoV-2 Vaccines. Clin Psychopharmacol Neurosci 2023; 21(2): 222–39.
<https://doi.org/10.9758/cpn.2023.21.2.222>
<PubMed>
2. F, May CA. COVID-19, post-acute COVID-19 syndrome (PACS, “long COVID”) and post-COVID-19 vaccination syndrome (PCVS, “post-COVIDvac-syndrome”): Similarities and differences. Pathol Res Pract 2023; 246: 154497.
<https://doi.org/10.1016/j.prp.2023.154497>
<PubMed>
3. M, Fouladi N, Golizadeh M, Shaker H, Matin S, Safarzadeh E. Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study. PLoS One 2024; 19(1): e0296669.
<https://doi.org/10.1371/journal.pone.0296669>
<PubMed>
4. SEF, Zhao Z, Kumanovics A, Love T, Meng QH, Wu AHB, Apple F, Ondracek CR, Schulz KM, Wiencek JR, Koch D, Christenson R, Zhang YV. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals. Front Public Health 2022; 10: 975781.
<https://doi.org/10.3389/fpubh.2022.975781>
<PubMed>
5. M, Hébert S, Wallukat G, Ponader R, Krickau T, Galiano M, Reutter H, Woelfle J, Agaimy A, Mardin C, Hoerning A, Hohberger B. “Multisystem Inflammatory Syndrome in Children” – Like Disease after COVID-19 Vaccination (MIS-V) with Potential Significance of Functional Active Autoantibodies Targeting G-Protein-Coupled Receptors (GPCR-fAAb) for Pathophysiology and Therapy. Children (Basel) 2023; 10(12): 1836.
6. CH, Heinze A, Karstedt S, et al. Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain Ther 2021: 1–22.
7. A, Janes F, Gigli GL, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin Neurol Neurosurg 2021; 208: 106839.
<https://doi.org/10.1016/j.clineuro.2021.106839>
<PubMed>
8. ST, Mohamed AS, Amar Z, Sarwar S, Ahmed Z. A Case of Acute Encephalitis in COVID-19 Patient: A Rare Complication. Cureus 2021; 13: e15636.
9. AA, Hasnie UA, Patel N, et al. Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord 2021; 21: 375.
<https://doi.org/10.1186/s12872-021-02183-3>
<PubMed>
10. M, Clemens SAC, Madhi SA, et al. Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397(10269): 99–111.
<https://doi.org/10.1016/S0140-6736(20)32661-1>
<PubMed>
11. J. Guillain-Barre syndrome 15 days after COVID-19 despite SARS-CoV-2 vaccination. IDCases 2021; 25: e01226.
<https://doi.org/10.1016/j.idcr.2021.e01226>
<PubMed>
12. CB, Choi JI, Hosseini F, Roberts J, Ramanathan K, Ong K. Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination. CJC Open 2021; 3(/11): 1410–12.
<https://doi.org/10.1016/j.cjco.2021.07.008>
<PubMed>
13. LJ, Rosen MP, Mittal K, et al. Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination. Cancer Treat Rev 2021; 98: 102220.
<https://doi.org/10.1016/j.ctrv.2021.102220>
<PubMed>
14. J, Cuevas-Castillo F, Nassar M, et al. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report. J Infect Public Health 2021; 14(10): 1392–4.
<https://doi.org/10.1016/j.jiph.2021.06.021>
<PubMed>
15. LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384: 403–16.
<https://doi.org/10.1056/NEJMoa2035389>
<PubMed>
16. E, Öğüt B, Erdem Ö, Öztaş MO, İlter N. Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single center. J Eur Acad Dermatol Venereol 2021; 35(12): e861–e864.
17. DS, Dardiotis E. Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns. Diagnostics (Basel) 2022; 12(7): 1555.
<https://doi.org/10.3390/diagnostics12071555>
<PubMed>
18. MN, Minassian AM, Ewer KJ, et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396(10267): 1979–93.
<https://doi.org/10.1016/S0140-6736(20)32466-1>
<PubMed>
19. PM, Ewer KJ, Aley PK, et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396(10249): 467–78.
<https://doi.org/10.1016/S0140-6736(20)31604-4>
<PubMed>
20. K, Berman G, Zhou H, et al. Evaluation of mRNA-1273SARS-CoV-2 Vaccine in Adolescents. N Engl J Med 2021; 385(24): 2241–51.
<https://doi.org/10.1056/NEJMoa2109522>
<PubMed>
